Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 209

1.

CCR5 receptor antagonism inhibits hepatitis C virus (HCV) replication in vitro.

Blackard JT, Kong L, Rouster SD, Karns R, Horn PS, Kottilil S, Shata MT, Sherman KE.

PLoS One. 2019 Oct 29;14(10):e0224523. doi: 10.1371/journal.pone.0224523. eCollection 2019.

2.

Quantification of Hepatitis B Surface Antigen: Is there a Role in HIV-Hepatitis B Virus Coinfection?

Jakharia N, Kottilil S, Chua JV.

AIDS Rev. 2019 Oct 3;21(3). [Epub ahead of print]

PMID:
31588136
3.

Metabolic Changes in Chronic Hepatitis C Patients who Carry IFNL4-ΔG and Achieve Sustained Virologic Response with Direct-Acting Antiviral Therapy.

Emmanuel B, El-Kamary SS, Magder LS, Stafford KA, Charurat ME, Chairez C, McLaughlin M, Hadigan C, Prokunina-Olsson L, O'Brien TR, Masur H, Kottilil S.

J Infect Dis. 2019 Aug 26. pii: jiz435. doi: 10.1093/infdis/jiz435. [Epub ahead of print]

PMID:
31504644
4.

Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study.

Lee KK, Stelzle D, Bing R, Anwar M, Strachan F, Bashir S, Newby DE, Shah JS, Chung MH, Bloomfield GS, Longenecker CT, Bagchi S, Kottilil S, Blach S, Razavi H, Mills PR, Mills NL, McAllister DA, Shah ASV.

Lancet Gastroenterol Hepatol. 2019 Oct;4(10):794-804. doi: 10.1016/S2468-1253(19)30227-4. Epub 2019 Jul 31.

5.

Long-term changes in hepatic fibrosis following hepatitis C viral clearance in patients with and without HIV.

Balmaceda JB, Aepfelbacher J, Belliveau O, Chaudhury CS, Chairez C, McLaughlin M, Silk R, Gross C, Kattakuzhy S, Rosenthal E, Kottilil S, Kleiner DE, Hadigan C.

Antivir Ther. 2019 Jul 30. doi: 10.3851/IMP3327. [Epub ahead of print]

PMID:
31359874
6.

What Matters Most for Treatment Decisions in Hepatitis C: Effectiveness, Costs, and Altruism.

Mattingly TJ 2nd, Slejko JF, Perfetto EM, Kottilil S, Mullins CD.

Patient. 2019 Jul 26. doi: 10.1007/s40271-019-00378-7. [Epub ahead of print]

PMID:
31347011
7.

Peripheral PD-1+ T Cells Co-expressing Inhibitory Receptors Predict SVR With Ultra Short Duration DAA Therapy in HCV Infection.

Romani S, Stafford K, Nelson A, Bagchi S, Kottilil S, Poonia B.

Front Immunol. 2019 Jun 27;10:1470. doi: 10.3389/fimmu.2019.01470. eCollection 2019.

8.

HIV and HCV augments inflammatory responses through increased TREM-1 expression and signaling in Kupffer and Myeloid cells.

Hyun J, McMahon RS, Lang AL, Edwards JS, Badilla AD, Greene ME, Stone GW, Pallikkuth S, Stevenson M, Dykxhoorn DM, Kottilil S, Pahwa S, Thomas E.

PLoS Pathog. 2019 Jul 1;15(7):e1007883. doi: 10.1371/journal.ppat.1007883. eCollection 2019 Jul.

9.

A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY).

Wilson E, Covert E, Hoffmann J, Comstock E, Emmanuel B, Tang L, Husson J, Chua J, Price A, Mathur P, Rosenthal E, Kattakuzhy S, Masur H, Kottilil S.

J Hepatol. 2019 Sep;71(3):498-504. doi: 10.1016/j.jhep.2019.05.021. Epub 2019 Jun 5.

PMID:
31173815
10.

Persistent gamma delta T-cell dysfunction in chronic HCV infection despite direct-acting antiviral therapy induced cure.

Ghosh A, Mondal RK, Romani S, Bagchi S, Cairo C, Pauza CD, Kottilil S, Poonia B.

J Viral Hepat. 2019 Sep;26(9):1105-1116. doi: 10.1111/jvh.13121. Epub 2019 May 26.

PMID:
31074195
11.

Hepatitis C core antigen testing: Still an effective diagnostic method for global elimination of hepatitis C.

Mathur P, Kottilil S.

Clin Infect Dis. 2019 Apr 3. pii: ciz273. doi: 10.1093/cid/ciz273. [Epub ahead of print] No abstract available.

PMID:
30943285
12.

Immunological recovery in T-cell activation after sustained virologic response among HIV positive and HIV negative chronic Hepatitis C patients.

Emmanuel B, El-Kamary SS, Magder LS, Stafford KA, Charurat ME, Poonia B, Chairez C, McLaughlin M, Hadigan C, Masur H, Kottilil S.

Hepatol Int. 2019 May;13(3):270-276. doi: 10.1007/s12072-019-09941-8. Epub 2019 Mar 5.

PMID:
30835046
13.

Testosterone in Men With Chronic Hepatitis C Infection and After Hepatitis C Viral Clearance.

Chaudhury CS, Mee T, Chairez C, McLaughlin M, Silk R, Gross C, Kattakuzhy S, Rosenthal E, Kottilil S, Stanley TL, Hadigan C.

Clin Infect Dis. 2019 Feb 2. doi: 10.1093/cid/ciy965. [Epub ahead of print]

PMID:
30715229
14.

Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era.

Mathur P, Kottilil S, Wilson E.

J Clin Transl Hepatol. 2018 Dec 28;6(4):431-437. doi: 10.14218/JCTH.2018.00007. Epub 2018 Sep 27. Review.

15.

Clinical features and determinants of chronicity in hepatitis E virus infection.

Narayanan S, Abutaleb A, Sherman KE, Kottilil S.

J Viral Hepat. 2019 Apr;26(4):414-421. doi: 10.1111/jvh.13059. Epub 2019 Feb 5. Review.

PMID:
30636092
16.

Multitarget Direct-Acting Antiviral Therapy Is Associated With Superior Immunologic Recovery in Patients Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus.

Shrivastava S, Bhatta M, Ward H, Romani S, Lee R, Rosenthal E, Osinusi A, Kohli A, Masur H, Kottilil S, Wilson E.

Hepatol Commun. 2018 Sep 27;2(12):1451-1466. doi: 10.1002/hep4.1258. eCollection 2018 Dec.

17.

Treatment of Chronic Hepatitis B Infection-Reply.

Tang L, Kottilil S.

JAMA. 2018 Sep 18;320(11):1202. doi: 10.1001/jama.2018.10021. No abstract available.

PMID:
30422297
18.

Characterization of changes in intrahepatic immune cell populations during HCV treatment with sofosbuvir and ribavirin.

Orr C, Aartun J, Masur H, Kottilil S, Meissner EG.

J Viral Hepat. 2019 Mar;26(3):323-328. doi: 10.1111/jvh.13034. Epub 2018 Dec 3.

PMID:
30383918
19.

Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C.

Tang L, Kamat M, Shukla A, Vora M, Kalal C, Kottilil S, Shah S.

Interdiscip Perspect Infect Dis. 2018 Oct 1;2018:9124604. doi: 10.1155/2018/9124604. eCollection 2018.

20.

HBV induces inhibitory FcRL receptor on B cells and dysregulates B cell-T follicular helper cell axis.

Poonia B, Ayithan N, Nandi M, Masur H, Kottilil S.

Sci Rep. 2018 Oct 17;8(1):15296. doi: 10.1038/s41598-018-33719-x.

21.

Mechanisms of neuropathogenesis in HIV and HCV: similarities, differences, and unknowns.

Abutaleb A, Kattakuzhy S, Kottilil S, O'Connor E, Wilson E.

J Neurovirol. 2018 Dec;24(6):670-678. doi: 10.1007/s13365-018-0678-5. Epub 2018 Oct 5. Review.

PMID:
30291565
22.

Improvement in Hepatic Fibrosis Biomarkers Associated With Chemokine Receptor Inactivation Through Mutation or Therapeutic Blockade.

Sherman KE, Abdel-Hameed E, Rouster SD, Shata MTM, Blackard JT, Safaie P, Kroner B, Preiss L, Horn PS, Kottilil S.

Clin Infect Dis. 2019 May 17;68(11):1911-1918. doi: 10.1093/cid/ciy807.

23.

Sofosbuvir/velpatasvir/voxilaprevir: a highly effective option for retreatment of hepatitis C in difficult-to-treat patients.

Mathur P, Kottilil S, Wilson E.

Antivir Ther. 2019;24(1):1-10. doi: 10.3851/IMP3264.

PMID:
30210057
24.

Using Stepwise Pharmacogenomics and Proteomics to Predict Hepatitis C Treatment Response in Difficult to Treat Patient Populations.

Naggie S, Clement M, Lusk S, Osinusi A, Himmel T, Lucas JE, Thompson WJ, Dubois L, Moseley MA, Clark PJ, Kottilil S, Patel K.

Proteomics Clin Appl. 2019 May;13(3):e1800006. doi: 10.1002/prca.201800006. Epub 2018 Aug 22.

PMID:
30058111
25.

Implementation of a unique hepatitis C care continuum model in Rwanda.

Mathur P, Comstock E, Makuza JD, Emmanuel B, Sebeza J, Kiromera A, Wilson E, Kattakuzhy S, Nelson A, Kottilil S, Riedel DJ.

J Public Health (Oxf). 2019 Jun 1;41(2):e203-e208. doi: 10.1093/pubmed/fdy115.

PMID:
29982813
26.

Global Burden of Atherosclerotic Cardiovascular Disease in People Living With HIV.

Shah ASV, Stelzle D, Lee KK, Beck EJ, Alam S, Clifford S, Longenecker CT, Strachan F, Bagchi S, Whiteley W, Rajagopalan S, Kottilil S, Nair H, Newby DE, McAllister DA, Mills NL.

Circulation. 2018 Sep 11;138(11):1100-1112. doi: 10.1161/CIRCULATIONAHA.117.033369.

27.

Shortening Treatment for Hepatitis C Virus Infection.

Kottilil S.

Gastroenterol Hepatol (N Y). 2018 Mar;14(3):186-188. No abstract available.

28.

Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy.

Abutaleb A, Kottilil S, Wilson E.

Hepatol Int. 2018 May;12(3):214-222. doi: 10.1007/s12072-018-9873-y. Epub 2018 May 29. Review.

29.

Chronic Hepatitis B Infection: A Review.

Tang LSY, Covert E, Wilson E, Kottilil S.

JAMA. 2018 May 1;319(17):1802-1813. doi: 10.1001/jama.2018.3795. Review. Erratum in: JAMA. 2018 Sep 18;320(11):1202.

PMID:
29715359
30.

Expansion of Treatment for Hepatitis C Virus Infection.

Emmanuel B, Masur H, Kottilil S, Kattakuzhy S.

Ann Intern Med. 2018 Mar 20;168(6):457-459. doi: 10.7326/L17-0698. No abstract available.

PMID:
29554678
31.

Eight Weeks of Ledipasvir/Sofosbuvir in Kidney Transplant Recipients With Hepatitis C Genotype 1 Infection.

Husson JS, Ravichandran B, Jonchhe S, Kottilil S, Wilson E.

Transplant Direct. 2017 Nov 3;3(12):e229. doi: 10.1097/TXD.0000000000000744. eCollection 2017 Dec.

32.

Time to end treatment restrictions for people with hepatitis C who inject drugs.

Rosenthal ES, Kattakuzhy S, Kottilil S.

Lancet Gastroenterol Hepatol. 2018 Mar;3(3):142-143. doi: 10.1016/S2468-1253(18)30001-3. Epub 2018 Jan 6. No abstract available.

PMID:
29310927
33.

Recovery of hepatitis C specific T-cell responses after rituximab therapy in hepatitis C mixed cryoglobulinemic vasculitis.

Mathur P, Emmanuel B, Sneller M, Zhang X, Poonia B, Kottilil S.

J Med Virol. 2018 May;90(5):936-941. doi: 10.1002/jmv.25002. Epub 2018 Jan 4.

34.

Transcriptional profiling of PBMCs unravels B cell mediated immunopathogenic imprints of HCV vasculitis.

Comstock E, Kim CW, Murphy A, Emmanuel B, Zhang X, Sneller M, Poonia B, Kottilil S.

PLoS One. 2017 Dec 11;12(12):e0188314. doi: 10.1371/journal.pone.0188314. eCollection 2017.

35.

Rapid changes in peripheral lymphocyte concentrations during interferon-free treatment of chronic hepatitis C virus infection.

Meissner EG, Kohli A, Higgins J, Lee YJ, Prokunina O, Wu D, Orr C, Masur H, Kottilil S.

Hepatol Commun. 2017 Sep;1(7):586-594. doi: 10.1002/hep4.1074. Epub 2017 Jul 24.

36.

No Improvement in Hemoglobin A1c Following Hepatitis C Viral Clearance in Patients With and Without HIV.

Chaudhury CS, Sheehan J, Chairez C, Akoth E, Gross C, Silk R, Kattakuzhy S, Rosenthal E, Kottilil S, Masur H, Hadigan C.

J Infect Dis. 2017 Dec 27;217(1):47-50. doi: 10.1093/infdis/jix517.

37.

IFNL4 Genotype Is Associated With Virologic Relapse After 8-Week Treatment With Sofosbuvir, Velpatasvir, and Voxilaprevir.

O'Brien TR, Kottilil S, Pfeiffer RM.

Gastroenterology. 2017 Dec;153(6):1694-1695. doi: 10.1053/j.gastro.2017.06.069. Epub 2017 Nov 3. No abstract available.

PMID:
29107709
38.

Vedroprevir in the management of hepatitis C virus infection.

Abutaleb A, Kottilil S.

Expert Opin Investig Drugs. 2017 Dec;26(12):1399-1402. doi: 10.1080/13543784.2017.1395412. Epub 2017 Oct 26. Review.

39.

Treatment of hepatitis C with 8 weeks of ledipasvir/sofosbuvir: Highly effective in a predominantly black male patient population.

Tang L, Parker A, Flores Y, Dellario M, Dickson C, Amoroso A, Kottilil S, Wilson E.

J Viral Hepat. 2018 Feb;25(2):205-208. doi: 10.1111/jvh.12796. Epub 2017 Oct 30. No abstract available.

PMID:
28984059
40.

A pilot study to expand treatment of chronic hepatitis C in resource-limited settings.

Mathur P, Comstock E, McSweegan E, Mercer N, Kumar NS, Kottilil S.

Antiviral Res. 2017 Oct;146:184-190. doi: 10.1016/j.antiviral.2017.09.007. Epub 2017 Sep 18.

PMID:
28927676
41.

The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?

Nguyen THT, Guedj J, Uprichard SL, Kohli A, Kottilil S, Perelson AS.

Sci Rep. 2017 Aug 31;7(1):10233. doi: 10.1038/s41598-017-09776-z.

42.

Factors associated with high cardiovascular risk in a primarily African American, urban HIV-infected population.

Bagchi S, Burrowes SA, Fantry LE, Hossain MB, Tollera GH, Kottilil S, Pauza CD, Miller M, Baumgarten M, Redfield RR.

SAGE Open Med. 2017 Aug 10;5:2050312117725644. doi: 10.1177/2050312117725644. eCollection 2017.

43.

Shortening the duration of therapy for chronic hepatitis C infection.

Emmanuel B, Wilson EM, O'Brien TR, Kottilil S, Lau G.

Lancet Gastroenterol Hepatol. 2017 Nov;2(11):832-836. doi: 10.1016/S2468-1253(17)30053-5. Epub 2017 Aug 10. Review.

44.

Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial.

Kattakuzhy S, Gross C, Emmanuel B, Teferi G, Jenkins V, Silk R, Akoth E, Thomas A, Ahmed C, Espinosa M, Price A, Rosenthal E, Tang L, Wilson E, Bentzen S, Masur H, Kottilil S; and the ASCEND Providers.

Ann Intern Med. 2017 Sep 5;167(5):311-318. doi: 10.7326/M17-0118. Epub 2017 Aug 8.

45.

Magnetic Resonance Elastography Shear Wave Velocity Correlates with Liver Fibrosis and Hepatic Venous Pressure Gradient in Adults with Advanced Liver Disease.

Gharib AM, Han MAT, Meissner EG, Kleiner DE, Zhao X, McLaughlin M, Matthews L, Rizvi B, Abd-Elmoniem KZ, Sinkus R, Levy E, Koh C, Myers RP, Subramanian GM, Kottilil S, Heller T, Kovacs JA, Morse CG.

Biomed Res Int. 2017;2017:2067479. doi: 10.1155/2017/2067479. Epub 2017 Apr 5.

46.

Patient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: The ASTRAL-5 study.

Younossi ZM, Stepanova M, Sulkowski M, Wyles D, Kottilil S, Hunt S.

Liver Int. 2017 Dec;37(12):1796-1804. doi: 10.1111/liv.13462. Epub 2017 May 25.

PMID:
28470938
47.

miRNA signatures can predict acute liver failure in hepatitis E infected pregnant females.

Trehanpati N, Sehgal R, Patra S, Vyas A, Vasudevan M, Khosla R, Khanam A, Kumar G, Maiwall R, Ramakrishna G, Kottilil S, Sarin SK.

Heliyon. 2017 Apr 6;3(4):e00287. doi: 10.1016/j.heliyon.2017.e00287. eCollection 2017 Apr.

48.

Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study.

Wyles D, Bräu N, Kottilil S, Daar ES, Ruane P, Workowski K, Luetkemeyer A, Adeyemi O, Kim AY, Doehle B, Huang KC, Mogalian E, Osinusi A, McNally J, Brainard DM, McHutchison JG, Naggie S, Sulkowski M; ASTRAL-5 Investigators.

Clin Infect Dis. 2017 Jul 1;65(1):6-12. doi: 10.1093/cid/cix260.

49.

Are we nearing the end in the fight against hepatitis C?

Chua JV, Kottilil S.

Expert Rev Gastroenterol Hepatol. 2017 Jun;11(6):499-500. doi: 10.1080/17474124.2017.1309287. Epub 2017 Mar 28. No abstract available.

PMID:
28335650
50.

Augmentation of hepatitis C virus-specific immunity and sustained virologic response.

Shrivastava S, Wilson E, Poonia B, Tang L, Osinusi A, Kohli A, Kottilil S.

J Viral Hepat. 2017 Sep;24(9):742-749. doi: 10.1111/jvh.12702. Epub 2017 May 4.

PMID:
28267900

Supplemental Content

Loading ...
Support Center